Obiettivo The global aim of RAPSODI is : · to develop a human vaccine candidate against most or all Leishmania species that cause the most severe leishmaniasis in the world. An unique vaccinal solution will thus be provided to protect against the various clinical phenotypes (namely visceral, cutaneous and mucocutaneaous leishmaniasis, VL, CL and ML respectively). · to establish all the associated procedures required for the subsequent clinical trials, such as the selection of the appropriate patients and assessment of vaccine efficiency. For that purpose, an international consortium constituted of countries from endemic areas (India, Peru, Tunisia, Spain and France) and embracing multi-disciplinary approaches has been set-up. Based on successful results on VL dogs, the best VL animal model to date, RAPSODI will propose a second generation human-compatible vaccine candidate and confirm its activity in pre-clinical studies. As the chosen antigen is common to most, if not all, Leishmania species, an ambitious universal immunoprotective response is being sought. RAPSODI will also address the question of population selection in order to ascertain relevant and meaningful clinical trials and vaccination campaigns. Indeed, resistant individuals, when involved in either vaccinated or placebo groups, represent important bias to the analysis of the results. RAPSODI will investigate further the parasitological, immunological and genetic features of such clinical status, and will subsequently apply the generated knowledge to the development of assays and field tests, which represent stand-alone results. The package (vaccine candidate + diagnostic/prognostic tools) proposed by RAPSODI represents a global solution, and as such is believed to have a real impact on the worldwide leishmaniasis problem. Campo scientifico agricultural sciencesanimal and dairy sciencedomestic animalsmedical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugsvaccines Parole chiave Leishmaniasis diagnosis efficacy follow-up leishmania pre-clinical trials resistance features vaccination vaccine vaccine candidate Programma(i) FP7-HEALTH - Specific Programme "Cooperation": Health Argomento(i) HEALTH-2007-2.3.4-2 - Development of a Leishmania vaccine Invito a presentare proposte FP7-HEALTH-2007-B Vedi altri progetti per questo bando Meccanismo di finanziamento CP-SICA - Collaborative project for specific cooperation actions dedicated to international cooperation partner countries (SICA) Coordinatore VIRBAC SA Contributo UE € 565 024,60 Indirizzo RUE 13EME LID 06511 CARROS Francia Mostra sulla mappa Regione Provence-Alpes-Côte d’Azur Provence-Alpes-Côte d’Azur Alpes-Maritimes Tipo di attività Private for-profit entities (excluding Higher or Secondary Education Establishments) Contatto amministrativo Cherifa Hemadou (Ms.) Collegamenti Contatta l’organizzazione Opens in new window Sito web Opens in new window Costo totale Nessun dato Partecipanti (8) Classifica in ordine alfabetico Classifica per Contributo UE Espandi tutto Riduci tutto INSTITUT DE RECHERCHE POUR LE DEVELOPPEMENT Francia Contributo UE € 404 093,00 Indirizzo BOULEVARD DE DUNKERQUE 44 CS 90009 13572 Marseille Mostra sulla mappa Regione Provence-Alpes-Côte d’Azur Provence-Alpes-Côte d’Azur Bouches-du-Rhône Tipo di attività Research Organisations Contatto amministrativo Ariel Crozon (Ms.) Collegamenti Contatta l’organizzazione Opens in new window Sito web Opens in new window Costo totale Nessun dato INSTITUTO DE SALUD CARLOS III Spagna Contributo UE € 554 300,80 Indirizzo MONFORTE DE LEMOS 5 28029 Madrid Mostra sulla mappa Regione Comunidad de Madrid Comunidad de Madrid Madrid Tipo di attività Research Organisations Contatto amministrativo Inmaculada Pastor (Ms.) Collegamenti Contatta l’organizzazione Opens in new window Sito web Opens in new window Costo totale Nessun dato INDIAN COUNCIL OF MEDICAL RESEARCHSOCIETY India Contributo UE € 330 840,00 Indirizzo ANSARI NAGAR 110029 New Delhi Mostra sulla mappa Tipo di attività Research Organisations Contatto amministrativo Sunita Saxena (Dr.) Collegamenti Contatta l’organizzazione Opens in new window Sito web Opens in new window Costo totale Nessun dato UNIVERSIDAD PERUANA CAYETANO HEREDIA Perú Contributo UE € 444 351,70 Indirizzo HONORIO DELGADO 430 31 Lima Mostra sulla mappa Tipo di attività Higher or Secondary Education Establishments Contatto amministrativo Oscar Situ (Dr.) Collegamenti Contatta l’organizzazione Opens in new window Sito web Opens in new window Costo totale Nessun dato INSTITUT PASTEUR DE TUNIS Tunisia Contributo UE € 300 175,70 Indirizzo Place Pasteur 13 1002 Tunis Mostra sulla mappa Tipo di attività Research Organisations Contatto amministrativo Faycal Chaabane (Mr.) Collegamenti Contatta l’organizzazione Opens in new window Sito web Opens in new window Costo totale Nessun dato AYMING Francia Contributo UE € 90 680,00 Indirizzo RUE CHAPTAL 114 92300 Levallois-Perret Mostra sulla mappa Regione Ile-de-France Ile-de-France Hauts-de-Seine Tipo di attività Private for-profit entities (excluding Higher or Secondary Education Establishments) Contatto amministrativo Frederic Peyrane (Dr.) Collegamenti Contatta l’organizzazione Opens in new window Sito web Opens in new window Costo totale Nessun dato INSTIMED Partecipazione conclusa Francia Contributo UE € 4 500,00 Indirizzo Rue Joseph Cugnot, Levée de Rochepinard 37702 Saint Pierre des Corps Mostra sulla mappa Tipo di attività Private for-profit entities (excluding Higher or Secondary Education Establishments) Contatto amministrativo Jean-Michel Bousquet (Mr.) Collegamenti Contatta l’organizzazione Opens in new window Costo totale Nessun dato SYNCROSOME SAS Francia Contributo UE € 43 183,20 Indirizzo AVENUE DE LUMINY - LUMINY BIOTECH CP 908 163 13288 MARSEILLE Mostra sulla mappa Tipo di attività Private for-profit entities (excluding Higher or Secondary Education Establishments) Contatto amministrativo Richard Mitry (Dr.) Collegamenti Contatta l’organizzazione Opens in new window Sito web Opens in new window Costo totale Nessun dato